Search - tctmd.com

Displaying 1 - 20 of 655

Sort: Relevancy | Date

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Daily News

Obama Signs 21st Century Cures Act Into Law

Caitlin E. Cox

December 15, 2016

News Daily News

Not Following NOAC Dosing Instructions Tied to Worse Clinical Outcomes

Todd Neale

December 12, 2016

News Industry News

Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA to Conduct U.S. Pivotal Study of the Carillon Mitral Contour System for Functional Mitral Regurgitation

December 01, 2016

News Daily News

Questions Over Risk-Benefit Balance for IVC Filters Still Vex Clinicians

Caitlin E. Cox

November 17, 2016

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Shelley Wood

November 13, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Todd Neale

November 04, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Anticipating FDA approval of the Amplatzer PFO Occluder: Indications, Rational Dispersion of Technology, and Post-Approval Studies

Presenter: Eustaquio Maria Onorato, Richard Smalling

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Possible Approval Pathways for New Mitral and Tricuspid Valve Therapies

Presenter: Matthew G. Hillebrenner, Michael J. Mack, John C Laschinger

November 01, 2016

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

Advertisement

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular News and Features for 2016

Obama Signs 21st Century Cures Act Into Law

Not Following NOAC Dosing Instructions Tied to Worse Clinical Outcomes

Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA to Conduct U.S. Pivotal Study of the Carillon Mitral Contour System for Functional Mitral Regurgitation

Questions Over Risk-Benefit Balance for IVC Filters Still Vex Clinicians

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Anticipating FDA approval of the Amplatzer PFO Occluder: Indications, Rational Dispersion of Technology, and Post-Approval Studies

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Possible Approval Pathways for New Mitral and Tricuspid Valve Therapies

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

FDA Perspectives on Short DAPT IDE Trials

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content